The pharmacy disclosure is the reason to read this row
Most sellers in this category describe their pharmacy partners by licensing class. They will tell you the pharmacy is a 503A, or that it follows certain standards, and stop there. That tells you what kind of entity is involved. It does not let you look anything up.
Ozari names two, each with a city, a state and an accrediting or certifying body. That moves the question from unanswerable to answerable. You can take those names to a state board register and read what the board says, which is a different activity from taking a company's word for it.
Ozari also states that the prescription label always identifies the pharmacy that prepared your medication. That is the part most readers will actually use, because it makes the disclosure checkable after the order rather than only before it. Naming a pharmacy is not a verdict on that pharmacy. It is the precondition for forming one.
Where the site contradicts itself, and what to do about it
The homepage says Ozari prescribes in all fifty states and prints a stat block saying the same. The pharmacy page says one of its two named pharmacies serves every state except nine, and that the other serves all fifty. Both pages were live on the same day.
There is no sentence anywhere saying which pharmacy fills which order, so there is no honest way to turn those two statements into a single answer. This site records the fifty-state claim as Ozari's published footprint, because that is what Ozari publishes as its footprint, and records the nine-state exclusion beside it as the finding it is.
For a reader in one of those nine states, that is not an abstraction. It is the difference between an order that ships and an order that does not, and the question to put to Ozari before paying is simply which of the two pharmacies will be filling yours.
What the prices are, and what they are not
Ozari publishes a starting figure for each of its two compounded drugs on the homepage, before any intake, with the billing period printed beside it. That is more than most of this field manages, and it is the reason this row exists at all.
They are starting figures, though, and no dose is attached to either one. A starting price is the bottom of a ladder, and Ozari does not show the ladder. Read the qualifier printed next to each figure on this page; on this provider it is carrying the whole caveat.
A branded option is mentioned on the partners page. No branded figure appears anywhere this site could find, and none has been invented here to fill the gap.
The membership question Ozari does not answer
Across eight pages, Ozari says nothing about a membership fee, a programme fee, a monthly fee or a platform fee in either direction. Not that one applies, and not that none does.
That matters because the phrase the site does use is a marketing one. Transparent pricing and no hidden fees is a claim about hiding, not a statement that no recurring charge exists. This roster records a membership as absent only when a seller says so in its own words, and Ozari has not.
Fifteen of the sixty-five sellers here are silent the same way. It is common, and it is still the question to ask at intake, because a headline figure and a bill are only the same thing when the seller says they are.
Who signs off on the medicine
Ozari names a clinical author with nursing credentials and a physician who medically reviewed the pharmacy page, and it carries a dated last-reviewed line. Author pages exist for several named people. Thirty-eight of the sixty-five sellers here name a prescriber, so this is not rare, but the dated review line is.
The homepage also carries an average-weight-loss percentage and a widget projecting a loss figure. Those are Ozari's claims about Ozari's patients. They are not repeated as findings here, and no reader should treat a marketing average as a forecast of their own result.
The medication is compounded, which means it has not been through the approval process an FDA-approved finished drug goes through. Ozari's naming of its pharmacies makes that fact easier to reason about, not less true.
Ozari Health's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $86/moStarting at, per month. The homepage prints "Starting at" above the figure and "/per month" beside it; the partners page repeats it as "Compounded and branded GLP-1 options starting at $86/month". No dose or plan length is attached to the figure anywhere it appears. | September 2026source |
| Tirzepatide (compounded) | $125/moStarting at, per month, in the same two-part label the homepage uses for semaglutide: "Starting at" above the figure and "/per month" beside it. No dose or plan length is attached to it. | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 65 providers reviewed here are paid partners today; the other 61 are not. See how this works.
See Ozari Health's current price →Good fit if
- Readers who will not buy a compounded medication from a company that refuses to say which pharmacy prepares it.
- Buyers who want a figure published on a public page, with its billing period, before handing over an email address.
- People who want to look a pharmacy up in a state register themselves rather than take a licensing class on trust.
- Readers who care that a clinical page carries a named reviewer and a date rather than an anonymous byline.
Look elsewhere if
- Anyone living in one of the nine states Ozari's own pharmacy page excludes, until Ozari says in writing which pharmacy will fill their order.
- Readers who need to know before they start whether a monthly membership sits underneath the medication price. Ozari does not say.
- Buyers who want an FDA-approved finished drug. A branded option is mentioned and never priced.
- People who need the price for the dose they will end up on rather than the dose they will start on.
How this review was verified
- Read the homepage in a browser rather than fetching its markup, and audited every dollar element on it for computed opacity, visibility and a real laid-out rectangle before recording a figure.
- Confirmed the same starting figure on a second page of the site, where it is printed with a space between the currency symbol and the number — a form that a naive price search returns nothing for.
- Read the pharmacy-standards page in full and logged both pharmacies, their cities, their accrediting bodies and the per-pharmacy state coverage sentences, then recorded the conflict with the homepage rather than resolving it.
- Treated the page listing all fifty state names as what it is — a directory of state landing pages — and did not count it as a coverage list. It carries fifty state names and no prices.
- Censused eight pages for any membership, programme-fee, monthly-fee or platform-fee sentence in either direction and found none, which is why the row records the question as unanswered rather than answered no.
- Searched the agency's published warning-letter record for the company name, 2017 to 2026, and found nothing. That search covers warning letters only; untitled letters are published separately and were not searched.